TEDA BIOMEDICAL(08189)
Search documents
泰达生物(08189) - 2019 - 年度财报
2020-04-28 11:34
Financial Performance - Total assets decreased to RMB 361,913,000 in 2019 from RMB 448,980,000 in 2018, representing a decline of approximately 19.4%[15] - Total liabilities remained relatively stable at RMB 156,406,000 in 2019 compared to RMB 157,312,000 in 2018, showing a slight decrease of 0.6%[15] - Shareholders' equity dropped significantly to RMB 191,034,000 in 2019 from RMB 273,006,000 in 2018, indicating a decrease of about 30.1%[15] - The company's revenue for the year ended December 31, 2019, was RMB 358,752,000, representing a year-on-year increase of 1.95%[22] - The gross profit for the same period was RMB 34,996,000, with a gross margin of 9.75%, an increase of 1,950.30% year-on-year[22] - The net loss attributable to shareholders was RMB 84,622,000, with a loss per share of RMB 4.47, a decrease of 53.34% compared to the previous year's loss of RMB 9.58 per share[22] - The total revenue for the year ended December 31, 2019, was RMB 358,751,734, representing a year-on-year increase of 1.95%[34] - The impairment loss of intangible assets for the year ended December 31, 2019, was RMB 12,881,908, a significant decrease from RMB 227,361,866 in the previous year[35] - Other income and losses netted RMB 7,937,281 for the year ended December 31, 2019, compared to RMB 3,680,687 in 2018, primarily due to a fair value loss of RMB 9,829,848 from EEG diagnostic intangible assets[39] - Sales and distribution costs decreased by 14.57% to RMB 18,561,353 for the year ended December 31, 2019, from RMB 21,726,586 in 2018, attributed to strict cost control measures[40] - Research and development expenses decreased by 28.88% to RMB 8,298,309 for the year ended December 31, 2019, down from RMB 11,667,239 in 2018, due to the completion of two research projects[41] - Financing costs increased by 67.82% to RMB 4,636,152 for the year ended December 31, 2019, from RMB 2,762,567 in 2018, due to increased interest expenses related to lease liabilities[43] - The company reported a loss attributable to owners of RMB 84,621,807 for the year ended December 31, 2019, compared to a loss of RMB 177,679,819 in 2018, with a loss per share of RMB 4.47[44] Business Operations - The company operates in two main business areas: bio-composite fertilizers and elderly care services, focusing on the needs of disabled and dementia patients[4] - The company is involved in the research, development, production, and sales of bio-composite fertilizers, targeting balanced growth for various crops[4] - The company has a diversified structure with subsidiaries focusing on health food, elderly care consulting, and soil remediation research[8] - The company aims to expand its elderly care services across the country, integrating management and operational resources[4] - The company is actively expanding its assistive device rental business, benefiting from government policies promoting this sector[22] - The company is adjusting its product structure to meet changing market demands and is focused on reducing production costs[22] - The company is committed to optimizing its internal organizational structure to ensure stable development of its compound fertilizer business[22] - The company plans to establish internationally leading proprietary elderly care institutions in the future[22] - The company is focusing on light asset operations in the elderly care sector, aiming to develop its own professional elderly care institutions in the future[30] - The company is actively promoting high-quality new fertilizers to adapt to changing market demands and improve soil health[29] - The company plans to continue expanding its assistive device rental business, establishing comprehensive systems, quality standards, and service processes[26] - The company aims to leverage its core advantages in the elderly care industry to provide management consulting services to other elderly care institutions[22] Strategic Initiatives - The company has completed acquisitions to enhance its capabilities in quantitative EEG detection and analysis technology, aiming to collaborate with medical institutions for accurate diagnosis[4] - The company has signed a strategic cooperation agreement with Almage Group, enhancing its capabilities in elderly care management[22] - A strategic cooperation agreement was signed with Almage Group to enhance the company's professional capabilities in Alzheimer's care and nursing home management[33] - The company has signed a framework agreement with Yangzhou Meilan Construction Management Co., Ltd. to provide management consulting services for a nursing home and rehabilitation hospital project[30] - The company plans to allocate approximately RMB 15,256,985 for expanding elderly care and health services, and RMB 6,538,708 for enhancing EEG diagnostic services[51] - The company anticipates reviewing and potentially changing the intended use of unutilized proceeds based on market conditions and operational needs[52] Market Conditions - The health and elderly care industry is experiencing rapid development, with the company focusing on providing management consulting services to elderly care institutions and developing its own high-end elderly care facilities in the future[26] - The fertilizer industry is facing new opportunities and challenges due to consumption upgrades and structural reforms in agricultural supply[24] - The company aims to enhance its competitiveness and accelerate product differentiation in response to the current overcapacity in the fertilizer industry[26] - The COVID-19 pandemic impacted market demand and logistics, but sales volume of compound fertilizers began to recover from February 2020[68] - The domestic market for brainwave detection systems is stabilizing, but the company is still seeking partners to expand its market presence[33] - The company is facing challenges in the fertilizer industry due to overcapacity and low demand, prompting a need for innovation and product upgrades[29] Governance and Compliance - The company has established a risk management and internal control system, which is reviewed at least annually to ensure its effectiveness[144] - The company has maintained a stable governance structure with independent directors and supervisors ensuring oversight and accountability[112] - The company has a diverse board with members holding various qualifications and experiences in finance and management[106] - The company has adhered to the corporate governance code, except for one provision during the review year[132] - The independent non-executive directors confirmed their independence according to GEM Listing Rules, ensuring compliance with governance standards[113] - The company has implemented measures to manage insider information and ensure confidentiality among insiders[150] - The board of directors is responsible for managing insider information, with the chairman being the main responsible person[148] - The company aims to ensure timely and reliable communication of information between the company and its shareholders[146] Environmental and Social Responsibility - The company has adopted sustainable development policies focusing on employment, labor practices, business integrity, and environmental and social principles[24] - The company emphasizes energy conservation, environmental protection, and the integration of social responsibility into its core business strategy[178] - The company encourages stakeholder engagement and feedback on its environmental, social, and governance (ESG) practices to enhance its performance[178] - The company adheres to various environmental laws and standards, including the "Environmental Protection Law of the People's Republic of China" and specific emission standards for water and air quality[183] - The company has established a comprehensive environmental management system to prevent pollution incidents during production[190] - The clean production initiatives led to a reduction of raw material usage by 10 tons per year, steam consumption by 30 tons per year, and electricity savings of 33,200 kWh per year[185] - The company has successfully reduced unorganized particulate emissions by 0.61 tons per year through its clean production efforts[185] - The company has maintained compliance with noise emission standards, ensuring that daytime noise levels do not exceed 60 dB(A) and nighttime levels do not exceed 50 dB(A)[185] Human Resources - The group employed 351 staff as of December 31, 2019, down from 531 in the previous year[64] - The company plans to increase its workforce by 15% to support its expansion and new product initiatives[100] - The attendance rates for board meetings and shareholder meetings were high, with the chairman attending all eight board meetings[143] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion[100] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[98] - The quantitative EEG detection technology is expected to become a profit growth point for the company despite its slow development currently[70]
泰达生物(08189) - 2019 Q3 - 季度财报
2019-11-13 11:38
Financial Performance - For the nine months ended September 30, 2019, the group achieved a consolidated revenue of RMB 284,497,765, representing a year-on-year increase of 5.76% compared to RMB 268,996,084 for the same period in 2018[6]. - The consolidated gross profit for the same period was RMB 30,848,000, which reflects a year-on-year decrease of 19.07% from RMB 38,118,816 in 2018[6]. - The loss attributable to equity holders of the company for the nine months ended September 30, 2019, was RMB 14,158,779, compared to a loss of RMB 59,054,824 for the same period in 2018, resulting in a basic loss per share of RMB 0.75[6]. - The group incurred a pre-tax loss of RMB 13,584,656 for the nine months ended September 30, 2019, compared to a pre-tax loss of RMB 56,712,046 in the same period of 2018[7]. - The company reported a net loss of RMB 13,548,651 for the nine months ended September 30, 2019, compared to a net loss of RMB 56,894,106 in 2018[7]. - The income tax expense for the nine months ended September 30, 2019, was RMB (36) compared to RMB 182 for the same period in 2018[10]. - For the nine months ended September 30, 2019, the total operating revenue was RMB 284,497,765, an increase of 5.76% compared to RMB 268,996,084 for the same period in 2018[18]. - The consolidated gross profit for the same period was RMB 30,848,000, a decrease of 19.07% from RMB 38,118,816 in 2018, resulting in a gross profit margin of 10.84%, down 3.33% from 14.17%[18]. - Basic loss per share was RMB 0.75, improved from RMB 3.366 in the previous year[13]. Dividend and Shareholder Information - The company did not recommend the payment of any dividend for the nine months ended September 30, 2019[6]. - The company does not recommend the payment of an interim dividend for the nine months ended September 30, 2019[14]. - As of September 30, 2019, Ms. Sun Li holds 300,000,000 shares, representing 15.83% of the issued share capital[23]. - Major shareholders include Tianjin TEDA International Entrepreneurship Center with 182,500,000 shares (9.63%) and Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%)[28]. - The company has not approved any new share option plans during the review period ending September 30, 2019[34]. - The company has not repurchased any of its shares during the review period[36]. Operational Insights - The company is involved in two main business areas: bio-composite fertilizers and healthcare services, focusing on elderly care and management[16]. - The company emphasizes the importance of compound fertilizers in agricultural production, which remains a significant industry affecting national livelihood[22]. - The company plans to optimize its internal organizational structure and reduce production costs to ensure stable development of its compound fertilizer business[22]. - The healthcare and elderly care industry is identified as a sunrise industry, with the company focusing on innovation and resource optimization to create new profit growth points[22]. - The company is actively seeking suitable properties and partners to expand its elderly care market[22]. - The company has initiated collaborations with private medical institutions for brainwave detection services and plans to continue diversifying its business model[22]. Governance and Compliance - The company has adhered to all provisions of the Corporate Governance Code except for A.2.1, which requires the roles of Chairman and CEO to be separate[38]. - From February 1, 2019, the company has complied with all other provisions of the Corporate Governance Code following the appointment of Mr. Yang as the new CEO[39]. - The audit committee has reviewed the group's performance for the nine months ending September 30, 2019[33]. Accounting Standards - The group adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2011, which did not have a significant impact on its unaudited operating results and financial position[8]. - The company continues to operate under the assumption of going concern, dependent on its future operational success[8]. Cost Management - The sales and distribution costs decreased by 20.00% to RMB 13,472,729 from RMB 16,839,040 in the previous year[18]. - Research and development and administrative expenses were RMB 29,011,540, a reduction of 10.80% compared to RMB 32,525,176 in 2018[18]. - Financing costs increased significantly by 588.76% to RMB 2,494,206 from RMB 362,130 in the previous year[18].
泰达生物(08189) - 2019 - 中期财报
2019-08-12 11:41
Financial Performance - For the six months ended June 30, 2019, the group achieved a consolidated revenue of RMB 200,755,549, representing a year-on-year increase of 13.92% compared to RMB 176,221,094 for the same period in 2018[6] - The consolidated gross profit for the same period was RMB 25,449,134, which reflects a year-on-year decrease of 10.74% from RMB 28,510,763 in 2018[6] - The loss attributable to equity holders of the company was RMB 6,835,079, a reduction of 16.50% compared to a loss of RMB 8,185,599 in the previous year[6] - The basic loss per share for the period was RMB 0.361, compared to RMB 0.467 for the same period in 2018[6] - The company reported a net loss before tax of RMB 6,047,281, compared to a loss of RMB 5,412,772 in the previous year, highlighting ongoing financial challenges[7] - The total revenue for the six months ended June 30, 2019, was RMB 200,751,856, representing a year-on-year increase of 13.92% compared to RMB 176,221,094 for the same period in 2018[39] - The comprehensive gross profit for the same period was RMB 25,449,134, which is a year-on-year decrease of 10.74% from RMB 28,510,763 in 2018, resulting in a gross profit margin of 12.67%, down 3.50% from 16.18% in 2018[39] Assets and Liabilities - The total assets of the company as of June 30, 2019, amounted to RMB 465,702,878, an increase from RMB 448,979,504 as of December 31, 2018[9] - Current assets increased to RMB 311,724,865 from RMB 293,901,494 in the previous year, driven by an increase in trade receivables[9] - Total current liabilities increased to RMB 175,442,951 as of June 30, 2019, from RMB 157,311,873 as of December 31, 2018, reflecting an increase of approximately 11.5%[10] - The company’s total equity attributable to owners decreased to RMB 265,461,060 as of June 30, 2019, from RMB 273,005,905 as of December 31, 2018, reflecting a decline of approximately 2.8%[10] - The total liabilities decreased from RMB 64,385,639 as of December 31, 2018, to RMB 46,543,013 as of June 30, 2019[30] - The total liabilities were approximately RMB 175,442,951, compared to RMB 157,311,873 as of December 31, 2018, resulting in a debt-to-asset ratio of 0.38[45] Cash Flow and Investments - Net cash used in operating activities for the six months ended June 30, 2019, was RMB (24,821,594), compared to RMB (32,883,274) in the same period of 2018, indicating an improvement of about 24%[12] - The company’s investment cash outflow for the six months ended June 30, 2019, was RMB (519,262), compared to RMB (4,529,723) in the same period of 2018, indicating a significant reduction in investment spending[12] - Cash and bank balances decreased to RMB 15,288,638 as of June 30, 2019, from RMB 52,979,680 as of June 30, 2018, representing a decline of approximately 71%[12] Operational Highlights - Research and development expenses for the period were RMB 20,445,159, compared to RMB 19,239,128 in the previous year, indicating a focus on innovation[7] - Sales and distribution costs decreased by 19.43% to RMB 9,636,063.96 for the six months ended June 30, 2019, compared to RMB 11,960,597 in the previous year[40] - Research and administrative expenses increased by 6.27% to RMB 20,445,160 for the same period, up from RMB 19,239,128 in 2018[41] - Interest expenses on bank loans for the six months ended June 30, 2019, were RMB 1,685,338, a decrease from RMB 1,827,771 in the same period of 2018, showing a reduction of about 7.7%[14] Shareholder Information - As of June 30, 2019, major shareholders included Tianjin TEDA International Entrepreneurship Center with a 9.63% stake and Shenzhen Xiangyong Investment Co., Ltd. with a 9.50% stake[55] - The company’s board members and supervisors collectively hold 300,000,000 shares, representing 15.83% of the issued share capital[52] - The weighted average number of ordinary shares for the calculation of basic loss per share was 1,894,500,000 for the six months ended June 30, 2019[22] Corporate Governance - The board of directors has complied with all corporate governance code provisions except for the separation of roles between the chairman and the CEO until February 1, 2019[65] - The audit committee reviewed the interim results and report for the six months ended June 30, 2019[60] - The company has maintained effective internal controls and risk assessment processes[59] Strategic Initiatives - The company is actively seeking partners and expanding its market for its EEG detection system, which has faced delays due to regulatory challenges and market conditions[37] - The company signed a strategic cooperation agreement with Almage Group for Alzheimer's care and nursing home management on March 30, 2019[37] - The company is developing a healthcare and elderly care industry holding platform to enhance its core competitiveness and create a new profit growth point[50] - The company aims to enhance its compound fertilizer business by ensuring product quality and expanding its customer base amid a stable supply-demand situation in the fertilizer industry[49] - The aging population in China has prompted the government to implement policies to support the development of the elderly care service industry, which the company is actively engaging in[50] Dividend and Share Transactions - The company did not recommend the payment of dividends for the six months ended June 30, 2019[6] - The company did not declare any interim dividend for the six months ended June 30, 2019[67] - There were no new share option schemes approved during the period ended June 30, 2019[61] - The company did not repurchase any of its shares during the review period[63] - There were no securities transactions by directors that violated the trading code during the review period[64]
泰达生物(08189) - 2019 Q1 - 季度财报
2019-05-10 11:38
法 天 津 泰 建 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號:8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司(「聯交所」)GEM的特色 GEM的定位,乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險,並應經過審慎周詳 的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司,在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險,同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責,對其準確性或完整性亦不 發表任何聲明,並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則(「GEM上市規則」)而刊載,旨在提供有關 天津泰達生物醫學工程股份有限公司(「本公司」)的資料;本公司董事願就本報告的 ...
泰达生物(08189) - 2018 - 年度财报
2019-03-29 11:39
Company Overview - The registered capital of Tianjin TEDA Biomedical Engineering Company Limited is RMB 189.045 million[4]. - Tianjin TEDA Biomedical Engineering Company Limited was officially listed on the Hong Kong GEM on June 18, 2002, under stock code 8189[4]. - The company operates in two main business areas: biological composite fertilizers and elderly care services, focusing on the elderly population with disabilities and dementia[4]. Business Operations - The biological composite fertilizer business includes a range of products aimed at promoting balanced growth of various crops[4]. - The company has completed acquisitions to exclusively own EEG quantitative detection and analysis technology, collaborating with medical institutions for accurate diagnosis of neurological and psychological diseases[4]. - The company is involved in the operation and management of elderly care facilities across the country, integrating resources and providing management consulting services[4]. - The company has a 100% ownership in Guangdong Welfare Dragon Composite Fertilizer Co., Ltd., which focuses on R&D, production, and sales of biological composite fertilizers[5]. - The company also holds a 51% stake in Shandong Haides Fertilizer Co., Ltd., which is engaged in similar fertilizer activities[5]. - The company has established a research institute for soil conditioning and restoration, focusing on regional soil resource management[5]. - The company is expanding its elderly care services and health management through various subsidiaries, including Beijing Hongdi Elderly Investment Management Co., Ltd.[5]. Financial Performance - The company reported a revenue of RMB 351,898,000 for the year ended December 31, 2018, representing a year-on-year decrease of 6.39%[18]. - The gross profit for 2018 was RMB 1,707,000, a significant decline of 96.79% compared to the previous year[18]. - The gross margin for 2018 was 0.49%, down from the previous year's margin, indicating a challenging operational environment[18]. - The attributable loss to shareholders for 2018 was RMB 177,680,000, with a loss per share of RMB 9.58, an increase of 1,068.29% from the previous year's loss per share of RMB 0.82[18]. - Total assets as of December 31, 2018, were RMB 448,980,000, a decrease from RMB 707,878,000 in 2017[10]. - Total liabilities increased to RMB 157,312,000 in 2018 from RMB 133,078,000 in 2017[10]. - The total revenue for the year ended December 31, 2018, was RMB 351,897,658, a decrease of 6.39% compared to RMB 375,906,530 in 2017[29]. - The comprehensive gross profit for the year was RMB 1,706,855, with a gross margin of 0.49%, down from 14.15% in the previous year[29]. - The impairment loss on intangible assets recognized for the year was RMB 227,361,866, attributed to changes in the Chinese market and business strategy[31]. - Other income and net losses for the year amounted to RMB 3,680,687, a decrease from RMB 5,377,946 in 2017[34]. - Research and development expenses for the year were RMB 11,667,239, an increase of 25.53% from RMB 9,294,266 in 2017[34]. - The administrative expenses for the year were RMB 32,195,141, a decrease of 11.13% from RMB 36,227,996 in the previous year[34]. Research and Development - The company has strengthened its R&D efforts in collaboration with the Chinese Academy of Agricultural Sciences to develop new fertilizer products[16]. - The company has launched a new brainwave detection service and established a new detection point in Xiamen[16]. - The company has developed new fertilizer products, including active shell chitosan soluble fertilizer and microbial fertilizers, which have received widespread recognition from farmers[24]. - The company has increased R&D efforts in organic fertilizers, with microbial fertilizers currently accounting for only about 7% of total fertilizer usage in China, compared to nearly 50% in developed countries[24]. - The company is committed to enhancing its core competitiveness through a technology innovation system that integrates market orientation and academic research[22]. - The company has established strategic collaborations with leading research institutions to develop new fertilizer products that meet green agricultural needs[24]. Elderly Care Services - The company won 8 projects in the Shanghai public bidding for elderly care services, aiming to provide rehabilitation and group therapy for 1,000 elderly individuals[16]. - The company aims to develop a professional elderly care industry chain in collaboration with top institutions in Europe, focusing on care for the elderly with disabilities and dementia[22]. - The company’s elderly care services are positioned to serve a wide demographic, including youth and the elderly, addressing various health management needs[25]. - The company has established a joint venture in Shandong to promote the "Shui Fa Rui Fu Elderly Care" brand and provide consulting services in elderly care management[29]. - The company is actively involved in international cooperation in the elderly care sector, partnering with French organizations to enhance service quality and operational standards[98]. Corporate Governance - The company is focusing on enhancing its corporate governance and risk management systems in compliance with GEM listing rules[19]. - The board of directors and management have been deemed to operate in compliance with laws and regulations, ensuring the protection of shareholder interests[68]. - The supervisory board held four meetings during the reporting period to review financial reports and ensure compliance with corporate governance[67]. - The company aims to enhance its internal control systems and governance structure in the upcoming year[70]. - The company has a strong management team with diverse backgrounds in finance, law, and healthcare, enhancing its operational capabilities[93][94][98]. - The board consists of nine members, including three executive directors, three non-executive directors, and three independent non-executive directors, ensuring compliance with GEM listing rules[124]. - The independent non-executive directors have confirmed their independence according to GEM listing rules, ensuring a balanced approach to shareholder interests[131]. Environmental Responsibility - The group focuses on environmental protection, with no significant pollution issues in its operations related to elderly care and health services[174]. - The company has implemented effective waste management practices, ensuring all solid waste is comprehensively utilized[177]. - The company has implemented advanced production processes, including high tower granulation and drum granulation, to minimize energy consumption and pollutant generation[186]. - Compliance with various environmental standards includes COD levels not exceeding 350 mg/L and ammonia levels not exceeding 20 mg/L in wastewater treatment agreements[188]. - The company plans to continue enhancing its environmental protection measures and resource utilization efficiency in future operations[196].